Monitor for additional closings of the private placement and any updates on Nasdaq stockholder approval. The company's ability to achieve positive monthly operating cash flow by Q1 2027 is a key catalyst; watch for revenue generation from cenplacel-L inventory deployment and manufacturing partnerships.
Price Chart
Executive Summary
Celularity announced an initial closing of a private placement of senior secured convertible notes and warrants generating over $10 million in gross proceeds, part of a broader recapitalization plan targeting up to $25 million in new capital and restructuring of ~$3 million in existing debt. The company reported Q4 2025 EPS of -$0.85 (a 44.4% beat vs consensus of N/A) and expects positive monthly operating cash flow by end of Q1 2027. The recapitalization and cost-cutting measures aim to support commercial execution and manufacturing expansion, but the company remains pre-revenue with no reported revenue in the filing.
Key Financial Metrics
Key Facts
- Initial closing of private placement of senior secured convertible notes and warrants generated over $10 million in gross cash proceeds
- Broader recapitalization plan contemplates up to $25 million in new cash investment and restructuring of approximately $3 million in existing indebtedness
- Q4 2025 EPS of -$0.85, a 44.4% beat vs consensus (estimate N/A)
- Company expects to achieve positive monthly operating cash flow by end of Q1 2027
- Monthly cash burn reduced by more than $1 million through operational improvements
- Existing cenplacel-L inventory estimated to represent approximately $40 million in potential sales value
- Philip A. Barach appointed to Board of Directors
- Notes mature 24 months after issuance, bear 10% interest, initially convertible at $1.50 per share; five-year warrants exercisable at $1.50 per share
Financial Impact
Up to $25 million in new capital raised through convertible notes and warrants, plus restructuring of ~$3 million in existing debt; Q4 2025 EPS -$0.85 (beat vs N/A estimate)
Risk Factors
- No assurance that additional closings of the private placement will occur
- Potential dilution from conversion of notes and exercise of warrants
- Company remains pre-revenue with no reported revenue in this filing; reliance on future funding and commercial execution
- Nasdaq listing compliance and delinquent SEC filing risks
- Cenplacel-L inventory may expire or become obsolete before monetization
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3368412 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 10-K/A | $1.26 | awaiting T+60 | — | $0.7500 (+40.48%) |
Sep 30, 2026 26d ago | Press Release | $1.35 | awaiting T+60 | — | $0.7500 (−44.44%) |
Sep 29, 2026 27d ago | 8-K | $1.35 | awaiting T+60 | — | $0.7500 (−44.44%) |
Sep 28, 2026 28d ago | SC 13D/A | $1.40 | awaiting T+60 | — | $0.7500 (+46.43%) |
Sep 28, 2026 29d ago | 8-K | $1.40 | awaiting T+60 | — | $0.7500 (+46.43%) |
Sep 24, 2026 4w ago | Press Release | $1.32 | awaiting T+60 | — | $0.7500 (−43.18%) |
Sep 14, 2026 6w ago | 8-K | $1.40 | awaiting T+60 | — | $0.7500 (−46.43%) |
Aug 25, 2026 8w ago | Press Release | $0.8804 | awaiting T+60 | — | $0.7500 (+14.81%) |
Aug 7, 2026 11w ago | 8-K | $0.6866 | awaiting T+60 | — | $0.7500 (−9.23%) |
Jun 30, 2026 16w ago | 8-K | $0.5979 $1.15 | ▼ −92.34% | ▼ −88.78% | $0.7500 (−25.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers